|
Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer? |
|
|
Consulting or Advisory Role - Bayer; Merck/Eisai |
Speakers' Bureau - Bayer; Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Calliditas Therapeutics; Cel-Sci; Merck |
Research Funding - AstraZeneca (Inst); Hookipa Pharma (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Regeneron (Inst) |
Patents, Royalties, Other Intellectual Property - anti-Staphylococcal Monoclonal antibody (Inst); Uptodate editor |
(OPTIONAL) Uncompensated Relationships - Vivan Therapeutics |